Artiva Biotherapeutics, Inc. Other Nonoperating Income (Expense)
Artiva Biotherapeutics, Inc. (ARTV) reported Other Nonoperating Income (Expense) of -$1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was -$1.00K.
- Artiva Biotherapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was $2.00K.
- Artiva Biotherapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was -$2.00K.
- Artiva Biotherapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was -$3.00K.
- Artiva Biotherapeutics, Inc. other nonoperating income (expense) for fiscal 2025 was -$14.00K, a 108.92% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. other nonoperating income (expense) for fiscal 2024 was $157.00K, a 19.49% decline from fiscal 2023.
- Artiva Biotherapeutics, Inc. other nonoperating income (expense) for fiscal 2023 was $195.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00K 10-Q · filed 2026-08-06 | $1.00K 10-Q · filed 2026-08-06 | -$1.00K derived: sum of 3 quarters · filed 2026-08-06 | -$4.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.00K 10-Q · filed 2026-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-05-08 | -$3.00K derived: sum of 3 quarters · filed 2026-05-08 | -$8.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$5.00K derived: sum of 2 quarters · filed 2026-03-10 | -$10.00K derived: sum of 3 quarters · filed 2026-08-06 | -$14.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | -$3.00K 10-Q · filed 2025-11-12 | -$8.00K derived: sum of 2 quarters · filed 2026-08-06 | -$12.00K 10-Q · filed 2025-11-12 | -$17.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$5.00K 10-Q · filed 2026-08-06 | -$8.00K 10-Q · filed 2026-08-06 | -$14.00K derived: sum of 3 quarters · filed 2026-08-06 | -$20.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$4.00K 10-Q · filed 2026-05-08 | -$9.00K derived: sum of 2 quarters · filed 2026-05-08 | -$15.00K derived: sum of 3 quarters · filed 2026-05-08 | $8.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$11.00K derived: sum of 2 quarters · filed 2026-03-10 | $12.00K derived: sum of 3 quarters · filed 2026-03-10 | $157.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | -$6.00K 10-Q · filed 2025-11-12 | $17.00K derived: sum of 2 quarters · filed 2025-11-12 | $162.00K 10-Q · filed 2025-11-12 | $332.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $23.00K 10-Q · filed 2025-08-06 | $169.00K 10-Q · filed 2025-08-06 | $338.00K derived: sum of 3 quarters · filed 2025-08-06 | $388.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $147.00K 10-Q · filed 2025-05-08 | $315.00K derived: sum of 2 quarters · filed 2025-05-08 | $365.00K derived: sum of 3 quarters · filed 2025-05-08 | $396.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $218.00K derived: sum of 2 quarters · filed 2025-03-24 | $249.00K derived: sum of 3 quarters · filed 2025-03-24 | $195.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $50.00K 10-Q · filed 2024-11-12 | $81.00K derived: sum of 2 quarters · filed 2024-11-12 | $27.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $31.00K 10-Q · filed 2024-08-29 | -$23.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |